Authors:
Hemming, AW
Gallinger, S
Greig, PD
Cattral, MS
Langer, B
Taylor, BR
Verjee, Z
Giesbrecht, E
Nakamachi, Y
Furuya, KN
Citation: Aw. Hemming et al., The hippurate ratio as an indicator of functional hepatic reserve for resection of hepatocellular carcinoma in cirrhotic patients, J GASTRO S, 5(3), 2001, pp. 316-321
Authors:
Cattral, MS
Greig, PD
Muradali, D
Grant, D
Citation: Ms. Cattral et al., Reconstruction of middle hepatic vein of a living-donor right lobe liver graft with recipient left portal vein, TRANSPLANT, 71(12), 2001, pp. 1864-1866
Authors:
Carpentier, A
Patterson, BW
Uffelman, KD
Giacca, A
Vranic, M
Cattral, MS
Lewis, GF
Citation: A. Carpentier et al., The effect of systemic versus portal insulin delivery in pancreas transplantation on insulin action and VLDL metabolism, DIABETES, 50(6), 2001, pp. 1402-1413
Authors:
Cattral, MS
Bigam, DL
Hemming, AW
Carpentier, A
Greig, PD
Wright, E
Cole, E
Donat, D
Lewis, GF
Citation: Ms. Cattral et al., Portal venous and enteric exocrine drainage versus systemic venous and bladder exocrine drainage of pancreas grafts - Clinical outcome of 40 consecutive transplant recipients, ANN SURG, 232(5), 2000, pp. 688-695
Citation: Aw. Hemming et Ms. Cattral, Ex vivo liver resection with replacement of the inferior vena cava and hepatic vein replacement by transposition of the portal vein, J AM COLL S, 189(5), 1999, pp. 523-526
Authors:
Hemming, AW
Cattral, MS
Greig, PD
Lilly, LB
Ashby, P
Levy, GA
Citation: Aw. Hemming et al., Domino liver transplantation for familial amyloid polyneuropathy: Optimal use of a scarce resource, TRANSPLAN P, 31(1-2), 1999, pp. 515-515
Authors:
Cattral, MS
Hemming, AW
Wanless, IR
Al Ashgar, H
Krajden, M
Lilly, L
Greig, PD
Levy, GA
Citation: Ms. Cattral et al., Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation, TRANSPLANT, 67(9), 1999, pp. 1277-1280
Authors:
Gorczynski, RM
Cattral, MS
Chen, ZG
Hu, JA
Lei, J
Min, WP
Yu, G
Ni, J
Citation: Rm. Gorczynski et al., An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival, J IMMUNOL, 163(3), 1999, pp. 1654-1660